These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32342945)

  • 1. Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.
    Nyunt WWT; Abdul Jalil D; Zakariah NA; Abdul Karim N; Mohd Idris MR; Nasuruddin DN; Salwati SHUIB; Alauddin H; Tumian NR; Leong CF; Abdul Wahid SFS
    Malays J Pathol; 2020 Apr; 42(1):143-150. PubMed ID: 32342945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
    Palazzo G
    Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.
    Obeidat MB; Al-Swailmeen AM; Arabeat AM; Abukamar AS
    Pan Afr Med J; 2020; 36():15. PubMed ID: 32774592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
    Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Telek B; Méhes L; Batár P; Kiss A; Udvardy M
    Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
    Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term complete remission in primary plasma cell leukemia.
    Tsuyuoka R; Takahashi T; Sasaki Y; Nakamura K; Fukumoto M; Kurisu Y; Tsubakimori K; Shioi K; Nakao K
    Intern Med; 1995 Apr; 34(4):251-4. PubMed ID: 7606092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
    Abu Zaanona MI; Patel P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
    Robak T; Urbańska-Rys H; Robak E; Bartkowiak J; Strzelecka B; Biernat W; Kordek R
    Leuk Lymphoma; 2002 May; 43(5):1067-73. PubMed ID: 12148888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
    Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
    J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
    Iino M; Nakajima A; Shindo H
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2441-3. PubMed ID: 19098420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
    Tang ASO; Ahmad Asnawi AW; Koh AZY; Chong SL; Liew PK; Selvaratnam V; Md Fauzi A; Lau NS; Tan SM
    Am J Case Rep; 2023 Mar; 24():e938868. PubMed ID: 36882990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
    Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
    Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.